Cargando…
Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission
Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is not yet well understood. Cancer survivors took 1.8, 3.6, or 5.4 g ABM granulated powder (Kyowa Wellness Co., Ltd., Tokyo, Japan) per day orally for 6 months. Adverse events wer...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092499/ https://www.ncbi.nlm.nih.gov/pubmed/21584278 http://dx.doi.org/10.1155/2011/192381 |
_version_ | 1782203376725917696 |
---|---|
author | Ohno, Satoshi Sumiyoshi, Yoshiteru Hashine, Katsuyoshi Shirato, Akitomi Kyo, Satoru Inoue, Masaki |
author_facet | Ohno, Satoshi Sumiyoshi, Yoshiteru Hashine, Katsuyoshi Shirato, Akitomi Kyo, Satoru Inoue, Masaki |
author_sort | Ohno, Satoshi |
collection | PubMed |
description | Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is not yet well understood. Cancer survivors took 1.8, 3.6, or 5.4 g ABM granulated powder (Kyowa Wellness Co., Ltd., Tokyo, Japan) per day orally for 6 months. Adverse events were defined by subjective/objective symptoms and laboratory data according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v3.0). Seventy-eight patients were assessed for safety of ABM (30/24/24 subjects at 1/2/3 packs per day, resp.). Adverse events were observed in 9 patients (12%). Most were digestive in nature such as nausea and diarrhea, and one patient developed a liver dysfunction-related food allergy, drug lymphocyte product. However, none of these adverse events occurred in a dose-dependent manner. This study shows that ABM does not cause problems in most patients within laboratory parameters at the dosages tested over 6 months. This trial supports previous evidence that the ABM product is generally safe, excluding possible allergic reaction. |
format | Text |
id | pubmed-3092499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30924992011-05-16 Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission Ohno, Satoshi Sumiyoshi, Yoshiteru Hashine, Katsuyoshi Shirato, Akitomi Kyo, Satoru Inoue, Masaki Evid Based Complement Alternat Med Research Article Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is not yet well understood. Cancer survivors took 1.8, 3.6, or 5.4 g ABM granulated powder (Kyowa Wellness Co., Ltd., Tokyo, Japan) per day orally for 6 months. Adverse events were defined by subjective/objective symptoms and laboratory data according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v3.0). Seventy-eight patients were assessed for safety of ABM (30/24/24 subjects at 1/2/3 packs per day, resp.). Adverse events were observed in 9 patients (12%). Most were digestive in nature such as nausea and diarrhea, and one patient developed a liver dysfunction-related food allergy, drug lymphocyte product. However, none of these adverse events occurred in a dose-dependent manner. This study shows that ABM does not cause problems in most patients within laboratory parameters at the dosages tested over 6 months. This trial supports previous evidence that the ABM product is generally safe, excluding possible allergic reaction. Hindawi Publishing Corporation 2011 2011-04-18 /pmc/articles/PMC3092499/ /pubmed/21584278 http://dx.doi.org/10.1155/2011/192381 Text en Copyright © 2011 Satoshi Ohno et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ohno, Satoshi Sumiyoshi, Yoshiteru Hashine, Katsuyoshi Shirato, Akitomi Kyo, Satoru Inoue, Masaki Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title | Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title_full | Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title_fullStr | Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title_full_unstemmed | Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title_short | Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission |
title_sort | phase i clinical study of the dietary supplement, agaricus blazei murill, in cancer patients in remission |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092499/ https://www.ncbi.nlm.nih.gov/pubmed/21584278 http://dx.doi.org/10.1155/2011/192381 |
work_keys_str_mv | AT ohnosatoshi phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission AT sumiyoshiyoshiteru phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission AT hashinekatsuyoshi phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission AT shiratoakitomi phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission AT kyosatoru phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission AT inouemasaki phaseiclinicalstudyofthedietarysupplementagaricusblazeimurillincancerpatientsinremission |